Factors driving oncologists' prescribing decisions for HER2-positive breast ... The Pharma Letter Afinitor/exemestane: Among surveyed oncologists who do not currently prescribe Afinitor (everolimus)/exemestane to their eligible HR-positive patients, high cost compared with generically available treatments and lack of familiarity with Afinitor ... |